Sophiris Bio prices IPO at $5, below expectations

By
A A A

Sophiris Bio, which is developing a biologic to treat enlarged prostates, raised $65 million by offering 13.0 million shares at $5. The company had previously filed to offer 5.0 million shares at $13. Sophiris Bio plans to list on the NASDAQ under the symbol SPHS. Sophiris Bio initially filed confidentially on 12/7/2012. Citi and Leerink Swann acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: SPHS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

86,627,350
  • $61.80 ▼ 3.33%
58,636,005
  • $15.44 ▼ 1.03%
43,254,709
  • $64.8725 ▼ 0.15%
39,355,269
  • $3.38 ▲ 0.90%
39,064,711
  • $4.29 ▲ 1.42%
38,037,134
  • $95.035 ▼ 0.37%
36,100,193
  • $94.66 ▼ 0.32%
32,857,379
  • $26.20 ▼ 0.46%
As of 7/10/2014, 04:04 PM